Buy PharmaCyte Biotech

In: Tips

29 Jun 2015

Hi Everybody,

If you’ve traded OTC stocks for a while, you know biotechs tend to lead the sector and produce the largest gainers.

Everyday there’s a new biotech running, creating profit opportunities for savvy traders.

With this in mind we found a nice looking biotech, that has proven to be a winner in the past.

This company has continued to release huge news since we last covered it and the stock is back in a nice range to enter for a winning trade.

Our alert for Monday is:
PharmaCyte Biotech, Inc.
Ticker symbol: PMCB
Last price: $0.109

PMCB is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box(R).

PMCB’s patented Cell-in-a-Box treatment, has earned FDA ‘orphan drug designation’, for the treatment of pancreatic cancer.  They will be executing Phase 2b of their clinical trials vs. a treatment using Eli Lilly’s Gemzar and Celgene’s Abraxane®.

Celgene is a billion dollar market cap company, and Eli Lilly is even bigger.  If PMCB’s trials are successful the result could be a wild ride for early investors.

PMCB’s research partner, the university of Northern Colorado (UNC), successfully obtained a Schedule 1 license from the DEA allowing the company to continue development of treatment by utilizing cannabinoid prodrugs in combination with Cell-in-a-Box®.  Now PMCB can dive deeper into experiments using cannabinoids.

In other recent news, PMCB showcased their technology and treatments to the media, large biotechnology firms and institutional investors at the 2015 BIO International Convention June 15th-18th.  The convention is the world’s largest biotechnology gathering with over 40,000 people attending.

According to the CEO, they were very busy at the convention with one meeting after another.

The prospects of PMCB continue to improve almost daily.

But even before the big break in their business, the sheer potential of this story as it makes its rounds could make for some major price swings.

The smallcap biotech sector is leading the market, and PMCB is a beautiful opportunity capitalizing on this trend.

The stock looks to be set for another run.

Make sure you’re ready to book your profits with PMCB!

Free Stock TipsAs always, do your own research, don’t chase gaps, use limit orders to enter positions, always use stop loss orders to protect your position, and take profits when you are in a position to do so.

Good Trading

Comment Form